Xilio Therapeutics (XLO) director receives grant of 5,000 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Xilio Therapeutics director Bello Akintunde Olatokumbo received a grant of stock options for 5,000 shares of common stock. The options carry an exercise price of 7.99 per share and expire on June 10, 2036.

The award will vest as to 100% of the underlying 5,000 shares on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders following the grant date, subject to his continued service. Following this grant, he holds 5,000 stock options, reflecting a routine compensation-related equity award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bello Akintunde Olatokumbo

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 5,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 5,000 options Exercise price: 7.99 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 5,000 options Stock Option (right to buy) granted on June 11, 2026

Exercise price 7.99 per share Exercise price for 5,000 options

Expiration date June 10, 2036 Option expiration for 5,000-share grant

Post-grant option holdings 5,000 options Total options held directly after transaction

Vesting date trigger Earlier of June 11, 2027 or next annual meeting 100% of shares vest subject to continued service

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "7.9900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The option was granted on June 11, 2026 and will vest as to 100% of the shares"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:08 PM Accepted by SEC EDGAR 06/12/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bello Akintunde Olatokumbo

(Last)

(First)

(Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.99	06/11/2026		A		5,000		⁽¹⁾	06/10/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Elana Brockmann, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did the Xilio Therapeutics (XLO) director report in this Form 4?

The Form 4 shows director Bello Akintunde Olatokumbo received stock options for 5,000 shares. These are compensation-related options, not an open-market trade, and give him the right to buy Xilio Therapeutics common stock at a fixed exercise price.

How many Xilio Therapeutics (XLO) stock options were granted and at what price?

The director was granted stock options over 5,000 shares of Xilio Therapeutics common stock. The options have an exercise price of 7.99 per share, meaning he can later purchase shares at that fixed price if the options vest.

When do the new Xilio Therapeutics (XLO) stock options vest?

The options will vest 100% on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders after the grant date. Vesting is conditioned on the director’s continued service with the company through that vesting date.

Are these Xilio Therapeutics (XLO) option transactions open-market buys or sells?

No, these are not open-market trades. The filing reports a compensation-related grant coded as “Grant, award, or other acquisition.” The company awarded the director stock options rather than him buying or selling existing Xilio Therapeutics shares in the market.

How many Xilio Therapeutics (XLO) options does the director hold after this grant?

After this transaction, the director holds 5,000 stock options in Xilio Therapeutics directly. This total matches the newly granted award, indicating this filing reflects his current option position reported as of the grant date in the Form 4.